Table 1.
The patients’ general clinicopathological characteristics and basic laboratory results.
| Feature | All | HPV(-) | HPV(+) | p |
|---|---|---|---|---|
| Demographic characteristics | ||||
| Age (years) | 60.62 ± 8.54 (30–80) | 60.85 ± 7.48 (37–79) | 60.36 ± 9.67 (30–80) | 0.745 |
| Male/female | 87 (68.5%)/40 (31.5%) | 51 (75.1%)/17 (25.0%) | 36 (61.0%)/23 (39.0%) | 0.133 |
| Weight (kg) | ||||
| Before treatment | 75.65 ± 15.24 (44–111) | 72.38 ± 15.24 (44–104.80) | 79.41 ± 14.64 (46–111) | 0.009 |
| After treatment | 71.88 ± 14.17 (42–110) | 70.56 ± 15.24 (42–94.70) | 72.96 ± 14.81 (45–110) | 0.419 |
| Weight difference (kg) | −5.08 ± 4.04 (−17.20–3.00) | −4.32 ± 3.71 (−12.00–3.00) | −5.71 ± 4.23 (−17.20–1.00) | 0.099 |
| Weight difference (%) | −6.49 ± 5.07 (−20.56–4.84) | −5.65 ± 4.85 (−19.35–4.84) | −7.19 ± 5.19 (−20.56–1.85) | 0.144 |
| BMI (kg/m2) groups | 0.371 | |||
| <18.5 | 5 (3.90%) | 4 (5.90%) | 1 (1.70%) | |
| >18.5 | 122 (96.10%) | 64 (94.10%) | 58 (98.30%) | |
| BMI (kg/m2) groups | 0.232 | |||
| <20 | 10 (7.90%) | 9 (13.20%) | 1 (1.70%) | |
| 20–25 | 39 (30.70%) | 24 (35.30%) | 15 (25.40%) | |
| 25–30 | 51 (40.20%) | 21 (30.90%) | 30 (50.80%) | |
| >30 | 27 (21.30%) | 14 (20.60%) | 13 (22.00%) | |
| NRS 2002 | ||||
| Before treatment | 0.35 ± 0.77 (0–4) | 0.41 ± 0.87 (0–4) | 0.28 ± 0.64 (0–4) | 0.680 |
| After treatment | 3.20 ± 1.11 (1–5) | 2.98 ± 1.09 (1–5) | 3.39 ± 1.10 (1–5) | 0.074 |
| Smoking | 0.0004 | |||
| No | 35 (27.60%) | 8 (11.80%) | 27 (45.80%) | |
| Yes | 74 (58.30%) | 51 (75.00%) | 23 (39.00%) | |
| Smoking cessation | 18 (14.20%) | 9 (13.20%) | 9 (15.30%) | |
| Alcohol | 0.012 | |||
| No | 41 (32.30%) | 15 (22.10%) | 26 (44.10%) | |
| Normal drinking | 83 (65.40%) | 50 (73.50%) | 33 (55.90%) | |
| Alcohol abuse | 3 (2.40%) | 3 (4.40%) | 0 (0.00%) | |
| Detailed tumor location | 0.010 | |||
| Tonsil | 91 (71.70%) | 44 (64.70%) | 47 (79.70%) | |
| Palate | 10 (7.90%) | 10 (14.70%) | 0 (0.00%) | |
| Root of the tongue | 22 (17.30%) | 13 (19.10%) | 9 (15.30%) | |
| Other oropharynx | 4 (3.10%) | 1 (1.50%) | 3 (5.10%) | |
| Histopathological grading | 0.049 | |||
| G1 | 7 (8.6%) | 6 (12.8%) | 1 (2.9%) | |
| G2 | 55 (67.9%) | 34 (72.3%) | 21 (61.8%) | |
| G3 | 18 (23.5%) | 7 (14.9%) | 12 (35.3%) | |
| Tumor depth (T) | 0.743 | |||
| T1 | 13 (10.2%) | 8 (11.8%) | 5 (8.5%) | |
| T2 | 42 (33.1%) | 24 (35.3%) | 18 (30.5%) | |
| T3 | 44 (34.6%) | 22 (32.4%) | 22 (37.3%) | |
| T4 | 27 (21.3%) | 13 (19.1%) | 14 (23.7%) | |
| Tx | 1 (0.8%) | 1 (1.5%) | 0 (0.0%) | |
| Lymph node metastasis (N) | 0.029 | |||
| N0 | 26 (20.50%) | 20 (29.40%) | 6 (10.20%) | |
| N1 | 26 (20.50%) | 16 (23.50%) | 10 (16.90%) | |
| N2 | 57 (44.90%) | 24 (35.30%) | 33 (55.90%) | |
| N3 | 17 (13.40%) | 8 (11.80%) | 9 (15.30%) | |
| Nx | 1 (0.80%) | 0 (0.00%) | 1 (1.70%) | |
| Clinical manifestation | ||||
| Pain | 73 (57.50%) | 39 (57.40%) | 34 (57.60%) | 0.882 |
| Neck mass | 46 (36.20%) | 17 (25.00%) | 29 (49.20%) | 0.008 |
| Cough | 6 (4.70%) | 5 (7.40%) | 1 (1.70%) | 0.215 |
| Hoarseness | 11 (8.70%) | 7 (10.30%) | 4 (6.80%) | 0.543 |
| Dysphagia | 34 (26.80%) | 19 (27.90%) | 15 (25.40%) | 0.906 |
| Dyspnea | 2 (1.60%) | 2 (2.90%) | 0 (0.00%) | 0.499 |
| Hemoptysis | 6 (4.70%) | 4 (5.90%) | 2 (3.40%) | 0.685 |
| Weight loss | 8 (6.30%) | 5 (7.40%) | 3 (5.10%) | 0.724 |
| Hearing impairment | 2 (1.60%) | 0 (0.00%) | 2 (3.40%) | 0.214 |
| Duration of medical history (months) | 5.55 ± 6.85 | 5.92 ± 60 | 5.13 ± 7.26 | 0.403 |
| Treatment duration (days) | 45.88 ± 9.76 | 43.64 ± 9.00 | 48.51 ± 10.04 | 0.005 |
| General treatment regimen | 0.003 | |||
| RT | 31 (24.4%) | 24 (35.3%) | 7 (11.9%) | |
| CRT | 96 (75.6%) | 44 (64.7%) | 52 (88.1%) | |
| Detailed treatment regimen | 0.006 | |||
| RT | 25 (19.70%) | 18 (26.50%) | 7 (11.90%) | |
| CRT | 51 (40.20%) | 18 (26.50%) | 33 (55.90%) | |
| pRT | 6 (4.70%) | 6 (8.80%) | 0 (0.00%) | |
| IndCT RT | 14 (11.00%) | 8 (11.80%) | 6 (10.20%) | |
| IndCT CRT | 30 (23.60%) | 17 (25.00%) | 13 (22.00%) | |
| Lymph node invasion according to treatment | ||||
| RT | 0.053 | |||
| N0–1 | 23 (74.19%) | 20 (87.00%) | 3 (13.00%) | |
| N2–3 | 8 (25.81%) | 4 (50.00%) | 4 (50.00%) | |
| CRT | 0.268 | |||
| N0–1 | 29 (30.20%) | 16 (55.20%) | 13 (44.80%) | |
| N2–3 | 67 (69.80%) | 28 (41.80%) | 39 (58.20%) |
Values are presented as means and standard deviations. BMI, body mass index; NRS 2002, Nutritional Risk Score 2002; CRP, C-reactive protein; PNI, prognostic nutritional index, RT, radiotherapy; CRT, chemoradiotherapy; pRT, postoperative radiotherapy; indCT, induction chemoradiotherapy.